I just added Cipher Pharma, CPHRF, to the portfolio. This is a very quick summary of the thesis. A full article will be forthcoming at some point, but I want to get something out there right away.

A remarkable opportunity to add to Cipher shares this morning emerged as Moberg, the company that makes Terclara, announced that the new dosing regimen in the US study failed. This is bad news for ...